Page last updated: 2024-11-02
pirenzepine and Dysthymia
pirenzepine has been researched along with Dysthymia in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Patients suffering from BPD and dysthymia were included in an 8-week, open-label study of olanzapine monotherapy." | 9.09 | Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. ( Berry, SA; Camlin, KL; Jesberger, JA; Schulz, SC, 1999) |
| "Patients suffering from BPD and dysthymia were included in an 8-week, open-label study of olanzapine monotherapy." | 5.09 | Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. ( Berry, SA; Camlin, KL; Jesberger, JA; Schulz, SC, 1999) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Schulz, SC | 1 |
| Camlin, KL | 1 |
| Berry, SA | 1 |
| Jesberger, JA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder[NCT00222482] | | 15 participants | Interventional | 2003-03-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for pirenzepine and Dysthymia